A large study examining ivermectin against COVID-19 included more participants than was reported in 2023, researchers acknowledged in a new correction. “The blinded statistical team made an error in the implementation of exclusion/inclusion criteria such that 106 participants in the ivermectin group and 120 participants in the placebo group who should have been included in the analysis cohort were not,” Dr. Naggie said.
She said the mistake stemmed from excluding participants who were listed as missing “study completion status.” “During the review process, staff in the unblinded statistical team did not identify the erroneous exclusion and thus the issue was not elevated for review,” according to Dr. Naggie, who said she was writing on behalf of her co-authors.
Dr. Naggie did not respond to requests for comment. Dr.
David Boulware, a scientist with the University of Minnesota and one of the co-authors, told The Epoch Times in an email that the error was identified when researchers were reporting the results from clinicaltrials.gov and found “that number of participants did not match up with the original publication, which then prompted further internal review in order to determine the source of the error.” The hazard ratio of time to recovery remained 1.
02, which is a non-statistically significant benefit for ivermectin recipients. The posterior probability for benefit from taking ivermectin was .65, lower than the original .
68. Both were beneath the prespecif.
